These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12208409)

  • 21. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
    Falcão LM; Pinto F; Ravara L; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytokines and remodeling of the heart in patients with congestive heart failure].
    Jołda-Mydłowska B; Salomon P
    Pol Arch Med Wewn; 2003 Jan; 109(1):23-33. PubMed ID: 12879763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
    White M; Rouleau JL; Afzal R; Floras J; Yusuf S; McKelvie RS
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):113-21. PubMed ID: 19299427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure].
    Latini R
    Ital Heart J Suppl; 2001 Jan; 2(1):83-4. PubMed ID: 11216088
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension.
    Millette E; Demeilliers B; Wu R; Laplante MA; El Midaoui A; Moreau P; Lamontagne D; de Champlain J
    J Hypertens; 2003 Jan; 21(1):125-35. PubMed ID: 12544444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure.
    Cha YM; Redfield MM; Shah S; Shen WK; Fishbein MC; Chen PS
    Heart Rhythm; 2005 Sep; 2(9):984-90. PubMed ID: 16171755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.
    Selvais PL; Robert A; Ahn S; van Linden F; Ketelslegers JM; Pouleur H; Rousseau MF
    J Card Fail; 2000 Sep; 6(3):201-7. PubMed ID: 10997745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation.
    Van Den Berg MP; Crijns HJ; Van Veldhuisen DJ; Griep N; De Kam PJ; Lie KI
    J Card Fail; 1995 Dec; 1(5):355-63. PubMed ID: 12836710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
    Davidson NC; Coutie WJ; Webb DJ; Struthers AD
    Heart; 1996 Jun; 75(6):576-81. PubMed ID: 8697160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy.
    Neuhold S; Huelsmann M; Strunk G; Struck J; Adlbrecht C; Gouya G; Elhenicky M; Pacher R
    Clin Chem; 2010 Jan; 56(1):121-6. PubMed ID: 19884490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
    Troughton RW; Rademaker MT; Powell JD; Yandle TG; Espiner EA; Frampton CM; Nicholls MG; Richards AM
    Hypertension; 2000 Oct; 36(4):523-30. PubMed ID: 11040230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
    Jourdain P; Funck F; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M; Duboc D
    Eur J Heart Fail; 2003 Mar; 5(2):155-60. PubMed ID: 12644005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopeptidase inhibition: a new direction in cardiovascular treatment.
    Asher JR; Naftilan AJ
    Curr Hypertens Rep; 2000 Aug; 2(4):384-91. PubMed ID: 10981174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
    Chen HH; Cataliotti A; Burnett JC
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
    Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
    Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
    Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.